2014, Number 3
Current management of arterial hypertension with olmesartan. Clinical experience in Mexican patients
Jiménez-Cruz JPM
Full text
Language: Spanish
References: 10
Page: 145-148
PDF size: 164.57 Kb.
ABSTRACT
A multicentre, observational, open-label, non-controlled trial was performed to evaluate the efficacy of Olmesartan at doses of 20 and 40 mg administered once daily in Mexican patients with arterial hypertension. Thirty nine cardiologists from 22 cities of the Mexican Republic participated, 350 patients were included (57% women and 43% men), with mean age of 59.25 ± 13.53 years within a range of 24 to 92 years. The mean values of systolic blood pressure at the initial and final visit were 152.8 ± 16.3 mmHg and 125.8 ± 10.9 mmHg, and those for diastolic blood pressure were 89.7 ± 11.3 mmHg and 77.0 ± 7.8 mmHg, respectively. According to t Student’s test, the reduction was statistically significant (p ‹ 0.01). To achieve these results, doses of 20 mg were administered to 36% of patients and 40 mg to 64%. An efficacy response to treatment was observed in 88% of the patients treated. Blood pressures lower than 140/90 mmHg or a reduction greater than 10% of the blood pressure figures relative to baseline values at the end of twelve weeks of treatment were considered an adequate response to treatment. Non-significant adverse events occurred at a rate lower than 4.2% of patients. Most were considered as known adverse events of the drug. We can conclude that the use of Olmesartan, proved to be an effective and safe antihypertensive drug in the treatment of systemic arterial hypertension in Mexican patients.REFERENCES